Caricamento...
A multicentre prospective cohort study assessing the effectiveness of budesonide MMX® (Cortiment®(MMX®)) for active, mild-to-moderate ulcerative colitis
BACKGROUND: Cortiment®(MMX®) (budesonide MMX®) is currently approved for the induction of remission in mild-to-moderate ulcerative colitis (UC) patients when 5-ASA treatment is not sufficient. Data in real-life settings are lacking. METHODS: This was a multicentre observational prospective cohort st...
Salvato in:
| Pubblicato in: | United European Gastroenterol J |
|---|---|
| Autori principali: | , , , , , , , , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
SAGE Publications
2019
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6826527/ https://ncbi.nlm.nih.gov/pubmed/31700630 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2050640619864848 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|